article

Manufacturing, Packaging & Logistics In-Depth Focus 2021

In this in-depth focus, find out about the key points to consider when implementing new software in the pharma development space and the current positions of the EMA and FDA with regards to nitrosamine contaminants.












    To read this in-depth focus in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of ACD/Labs

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    • Using software to improve data management and output in pharma development
      The COVID-19 pandemic has exposed various issues with the software and data processes employed in the pharmaceutical industry and spurred rapid digital transformation at a rate never before seen in the sector. In this article, Jordan Stobaugh, Principal Research Scientist at AbbVie, discusses how software can improve data management and the key points to consider when looking to implement new data technology.
    • Nitrosamines: the latest position
      Timelines for assessing the potential for contamination of medicinal compounds with nitrosamines have been revised. Here, Dave Elder explains the EMA’s and FDA’s positions and the likely scenarios to be encountered.
    Send this to a friend